Quantum Pharma PLC Posting of Circular (2193N)

TIDMQP.

RNS Number : 2193N

Quantum Pharma PLC

21 October 2016

 
   21 October 2016 
 

This announcement contains inside information

Quantum Pharma Plc

('Quantum', the 'Group' or the 'Company')

Posting of Circular

Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that further to the statement made by the Company on 20 October 2016 concerning the "Confirmation of successful GBP15 million fundraise subject to shareholder approval", the Company has today posted a circular to its shareholders convening a General Meeting of the Company to be held on 10 November 2016 at 11.00 a.m. at the offices of Muckle LLP, Time Central, 32 Gallowgate, Newcastle upon Tyne, NE1 4BF.

A copy of the circular will shortly be available on the Company's investor relations website http://ir.quantumpharmagroup.com/ .

- Ends -

For further information:

 
 Quantum Pharma Plc                           Tel: [phone] 
                                                        279 404 
 Chris Rigg, CEO & CFO                 www.quantumpharmaplc.com 
  Craig Swinhoe, Group Strategic 
  Projects Director and Company 
  Secretary 
 
 Zeus Capital Limited                           Tel: +44 (0) 20 
  (Nominated Adviser & Joint                          3829 5000 
  Broker)                                 www.zeuscapital.co.uk 
 Andrew Jones / Nick Cowles 
  / Jamie Peel 
 Dominic Wilson / Adam Pollock 
  / John Goold 
 
   N+1 Singer                                   Tel: +44 (0) 20 
   (Joint Broker)                                     7496 3000 
   Aubrey Powell / James White                 www.n1singer.com 
   / Sandy Ritchie 
   Nick Owen / Brough Ransom 
 Media enquiries: 
 Buchanan 
 Henry Harrison-Topham / Sophie                 Tel: +44 (0) 20 
  Cowles / Steph Watson                               7466 5000 
 [e-mail]              www.buchanan.uk.com 
 
 

Notes to Editors

Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

Specials comprises four business units (Quantum Pharmaceutical, UL Medicines, NuPharm and Quantum Aseptics Services), which manufacture, procure and supply unlicensed medicines (specials) and special obtains. In response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment, the division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products. With an expansive portfolio of products, Quantum is a trusted partner to the majority of large retail pharmacy chains in the UK, as well as pharmaceutical wholesalers, hospitals, independent pharmacies and dispensing doctors. The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.

Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products) which develop and commercialise niche pharmaceuticals. This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets gained through our Specials and Medication Adherence divisions, to allow early identification of the market opportunity to take products from unlicensed (special) status to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.

Medication Adherence comprises two business units (Biodose(R) and Biodose Services(R)) which provide products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose(R), the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect(TM) takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies across the UK and provides the Group with exposure to the homecare and supported living sectors of the care pathway complementing the focus of the remainder of the Group.

For further information, please visit www.quantumpharmaplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

CIRMMMZGKMFGVZM

(END) Dow Jones Newswires

October 21, 2016 11:20 ET (15:20 GMT)